DKC1 upregulation is associated with poor prognosis in patients with prostate cancer, neuroblastoma, and hepatocellular carcinoma.27–29 These findings are consistent with our studies showing that upregulated DKC1 expression is correlated with poor 5-year overall and disease-specific cumulative survival in patients with CRC (Fig. 1e, f). Here, DKC1 is linked to prostate cancer.